Treatment of disorders secondary to organic impairments

Abstract

A method for treatment of neuropsychiatric symptoms or disorders emanating from primary brain or systemic impairments includes administration of an effective dose of a dopamine, serotonin, and norepinephrine reuptake inhibitor to a human in need of such treatment. The preferred reuptake inhibitor is sibutramine.

What is claimed:  
     
         1 . A method of treatment for neurological, behavioral and cognitive disorders or symptoms, emanating from primary organic impairments which comprise temporal lobe epilepsy; brain disorders of metabolic, endocrine, genetic, or chromosomal diseases, brain cysts and tumors; or viral infection, said method comprising administering to a human in need of such treatment a pharmaceutically effective amount of a compound which is a selective reuptake inhibitor for dopamine, serotonin and norepinephrine.  
     
     
         2 . The method of  claim 1  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         3 . The method of  claim 2  wherein the treatment interrupts endorphin-opioid pathology.  
     
     
         4 . The method of  claim 1  wherein the pharmaceutically effective amount comprises from about 0.25 mg to about 45 mg per day.  
     
     
         5 . A method for treatment of symptoms of Sick Building Syndrome comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.  
     
     
         6 . The method of  claim 5  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         7 . A method for treatment of symptoms of Gulf War Syndrome comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.  
     
     
         8 . The method of  claim 7  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         9 . A method for treatment of symptoms of Reflex Sympathetic Dystrophy Syndrome or Complex Regional Pain Syndrome comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.  
     
     
         10 . The method of  claim 9  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         11 . A method for treatment of symptoms of Retinitis Pigmentosa comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.  
     
     
         12 . The method of  claim 11  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         13 . A method for treatment of symptoms of organic brain impairments which result in stammering comprising administering a pharmaceutically effective amount of a selective reuptake inhibitor for dopamine, serotonin and norepinephrine thereof to a human in need of such treatment.  
     
     
         14 . The method of  claim 13  wherein the dopamine, serotonin and norepinephrine reuptake inhibitor is sibutramine, sibutramine salts or derivatives of sibutramine.  
     
     
         15 . A method for treatment of claims  6 ,  8 ,  10 ,  12  or  14  wherein the pharmaceutically effective amount comprises about 0.25 mg to about 45 mg per day.  
     
     
         16 . A method for treatment of claims  6 ,  8 ,  10 ,  12  or  14  further comprising delivering said pharmaceutically acceptable amount in a controlled or sustained release form.  
     
     
         17 . The method for treatment of claims  6 ,  8 ,  10 ,  12 , or  14  further including an antiepileptic or anti-depressant medication.